| Citation: |
LIU Yingbo, LIU Xiaohong, RU Meihua, LI Jianqiang. Expression of MAD2L1 in Lung Adenocarcinoma and Its Effect on Immune Microenvironment[J]. Cancer Research on Prevention and Treatment, 2022, 49(6): 586-592. DOI: 10.3971/j.issn.1000-8578.2022.21.1222
|
To investigate the expression of MAD2L1 in lung adenocarcinoma and its effect on the prognosis and immune microenvironment of patients.
The difference of MAD2L1 expression in lung adenocarcinoma tissue and normal lung tissue was analyzed by TCGA and GEO database. Survival analysis was carried out to evaluate the prognostic significance of MAD2L1 gene expression in lung adenocarcinoma patients. StarBase database was used to construct miRNA-MAD2L1 regulatory network of lung adenocarcinoma. The relation between the expression of MAD2L1 and immune cell infiltration in lung adenocarcinoma was analyzed by TIMER database.
The expression of MAD2L1 was up-regulated in lung adenocarcinoma, and the high expression of MAD2L1 was significantly correlated with pathological stage and lymph node metastasis of lung adenocarcinoma. The patients with high expression of MAD2L1 had a poor prognosis. miR-101-3p/MAD2L1 axis was identified as the most potential upstream regulation pathway of MAD2L1 in lung adenocarcinoma. The expression level of MAD2L1 was significantly correlated with tumor immune cell infiltration and immune checkpoint expression.
MAD2L1 is highly expressed in lung adenocarcinoma, which is related to poor prognosis and tumor immune infiltration. MAD2L1 can be used as a potential target for the treatment of lung adenocarcinoma.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics[J]. Adv Exp Med Biol, 2016, 893: 1-19.
|
| [2] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
|
| [3] |
Eanes WF. New views on the selection acting on genetic polymorphism in central metabolic genes[J]. Ann N Y Acad Sci, 2017, 1389(1): 108-123. doi: 10.1111/nyas.13285
|
| [4] |
Xu XH, Kou LC, Wang HM, et al. Genetic polymorphisms of melatonin receptors 1A and 1B may result in disordered lipid metabolism in obese patients with polycystic ovary syndrome[J]. Mol Med Rep, 2019, 19(3): 2220-2230.
|
| [5] |
Luo C, Lei M, Zhang Y, et al. Systematic construction and validation of an immune prognostic model for lung adenocarcinoma[J]. J Cell Mol Med, 2020, 24(2): 1233-1244. doi: 10.1111/jcmm.14719
|
| [6] |
Foijer F, Albacker LA, Bakker B, et al. Deletion of the MAD2L1 spindle assembly checkpoint gene is tolerated in mouse models of acute T-cell lymphoma and hepatocellular carcinoma[J]. Elife, 2017, 6: e20873. doi: 10.7554/eLife.20873
|
| [7] |
Kim Y, Choi JW, Lee JH, et al. Spindle assembly checkpoint MAD2 and CDC20 overexpressions and cell-in-cell formation in gastric cancer and its precursor lesions[J]. Hum Pathol, 2019, 85: 174-183. doi: 10.1016/j.humpath.2018.10.029
|
| [8] |
Chandrashekar DS, Bashel B, Balasubramanya AH, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses[J]. Neoplasia, 2017, 19(8): 649-658. doi: 10.1016/j.neo.2017.05.002
|
| [9] |
Li T, Fan J, Wang B, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells[J]. Cancer Res, 2017, 77(21): e108-e110. doi: 10.1158/0008-5472.CAN-17-0307
|
| [10] |
Leal-esteban LC, Fajas L. Cell cycle regulators in cancer cell metabolism[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(5): 165715. doi: 10.1016/j.bbadis.2020.165715
|
| [11] |
Niwa M. A cell cycle checkpoint for the endoplasmic reticulum[J]. Biochim Biophys Acta Mol Cell Res, 2020, 1867(12): 118825. doi: 10.1016/j.bbamcr.2020.118825
|
| [12] |
Alikhanyan K, Chen Y, Somogyi K, et al. Mad2 Induced Aneuploidy Contributes to Eml4-Alk Driven Lung Cancer by Generating an Immunosuppressive Environment[J]. Cancers(Basel), 2021, 13(23): 6027.
|
| [13] |
Wenzel ES, Singh TK. Cell-cycle Checkpoints and Aneuploidy on the Path to Cancer[J]. In vivo, 2018, 32(1): 1-5.
|
| [14] |
Gay S. A novel function for the mitotic checkpoint protein Mad2p in translation[J]. Mol Cell Oncol, 2018, 5(4): e1494949. doi: 10.1080/23723556.2018.1494949
|
| [15] |
Zhu XF, Yi M, He J, et al. Pathological significance of MAD2L1 in breast cancer: an immunohistochemical study and meta analysis[J]. Int J Clin Exp Pathol, 2017, 10(9): 9190-9201.
|
| [16] |
Li Y, Bai W, Zhang J. MiR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma (HCC) via suppressing MAD2L1[J]. Biomed Pharmacother, 2017, 92: 1038-1044. doi: 10.1016/j.biopha.2017.05.092
|
| [17] |
Wang Y, Wang F, He J, et al. miR-30a-3p Targets MAD2L1 and Regulates Proliferation of Gastric Cancer Cells[J]. Onco Targets Ther, 2019, 12: 11313-11324. doi: 10.2147/OTT.S222854
|
| [18] |
Lin X, Zhou M, Xu Z, et al. Bioinformatics study on genes related to a high-risk postoperative recurrence of lung adenocarcinoma[J]. Sci Prog, 2021, 104(3): 368504211018053.
|
| [19] |
Shi YX, Zhu T, Zou T, et al. Prognostic and predictive values of CDK1 and MAD2L1 in lung adenocarcinoma[J]. Oncotarget, 2016, 7(51): 85235-85243. doi: 10.18632/oncotarget.13252
|
| [20] |
Meng X, Sun Y, Liu S, et al. miR-101-3p sensitizes lung adenocarcinoma cells to irradiation via targeting BIRC5[J]. Oncol Lett, 2021, 21(4): 282. doi: 10.3892/ol.2021.12543
|
| [21] |
Liu SH, Hsu KW, Lai YL, et al. Systematic identification of clinically relevant miRNAs for potential miRNA-based therapy in lung adenocarcinoma[J]. Mol Ther Nucleic Acid, 2021, 25: 1-10. doi: 10.1016/j.omtn.2021.04.020
|
| [22] |
Waniczek D, Lorenc Z, Śnietura M, et al. Tumor-Associated Macrophages and Regulatory T Cells Infiltration and the Clinical Outcome in Colorectal Cancer[J]. Arch Immunol Ther Exp(Warsz), 2017, 65(5): 445-454. doi: 10.1007/s00005-017-0463-9
|
| [23] |
Zhang H, Liu H, Shen Z, et al. Tumor-infiltrating Neutrophils is Prognostic and Predictive for Postoperative Adjuvant Chemotherapy Benefit in Patients With Gastric Cancer[J]. Ann Surgery, 2018, 267(2): 311-318. doi: 10.1097/SLA.0000000000002058
|
| [24] |
Lyu L, Yao J, Wang M, et al. Overexpressed Pseudogene HLA-DPB2 Promotes Tumor Immune Infiltrates by Regulating HLA-DPB1 and Indicates a Better Prognosis in Breast Cancer[J]. Front Oncol, 2020, 10: 1245. doi: 10.3389/fonc.2020.01245
|
| [25] |
Chae YK, Arya A, Iams W, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)[J]. J Immunother Cancer, 2018, 6(1): 39. doi: 10.1186/s40425-018-0349-3
|
Figures(5) / Tables(2)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: